19th Annual International Ultmann Chicago Lymphoma Symposium April 29-30, 2022

Accreditation and Credit Designation Statement

Description

Scientific innovation in the detection and treatment of lymphoma is rapidly advancing, and practicing physicians cannot keep abreast of the latest developments in the area. By educating healthcare providers on the current publications and lymphoma data, patients will receive the best and most relevant treatment of their disease

Target Audience

The symposium has been designed for medical hematologists/oncologists, radiation oncologists, pathologists, surgical oncologists, fellows-in-training, oncology nurses, and allied health professionals committed to the diagnosis and treatment of lymphoma.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  • Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma;
  • Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma;
  • Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data;
  • Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL;
  • Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.

Accreditation And Credit Designation

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

The University of Chicago Medicine is an approved provider of continuing nursing education by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91)

This live activity is designated for a maximum of 14.5 continuing nursing education units.

American Board of Internal Medicine MOC Part II Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Healthcare Professions Credit

Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME, please consult your professional licensing board.

Educational Grants/Commercial Support

Educational grant funding has been generously provided by:

AbbVie, Inc.

AstraZeneca Pharmaceuticals

Genentech, Inc.

Genmab

Janssen Scientific Affairs, LLC

Morphosys

Novartis Corporation

Seagen

We also thank our sponsors/exhibitors:

Platinum Level

ADC Therapeutics

Genmab


Gold Level

AstraZeneca

BeiGene

Pharmacyclics

Seagen


Silver Level

AbbVie

Alexion

Bristol Myers Squibb

Cellectar Biosciences

Genentech

Incyte

Karyopharm

Kite

Morphosys

PharmaEssentia

Rigel

Sanofi

Servier

Disclosure Declarations

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

The staff of the Center for Continuing Medical Education, Bio Ascend, and Meeting Achievements have disclosed that they have no relevant financial relationships with ACCME defined commercial interests

Course Faculty

The following faculty and planners have disclosed that they have no relevant financial relationships with ACCME defined commercial interests in the past twelve months:

Kenneth S. Cohen, MD

Nicole Anne C. Soriano, PharmD

Leo I. Gordon, MD

Katherine Thorp, DNP

Nasheed M. Hossain, MD

Lindsay M. Morton, PhD

Paul Rubinstein, MD

Sairah Ahmed, MD receives research funding from Tessa Therapeutics, SeaGen, Merck, and Xencor, and serves on the advisory committee for Sanofi, SeaGen, and Tessa Therapeutics. She serves as a consultant for Novartis, Myeloid Therapeutics, and Servier.

Rajat Bannerji, MD, PhD receives grant funding from Regeneron Pharmaceuticals, AbbVie, Genetech/Roche, Pharmacyclics, and Merck & Co.

Tracy Batchelor, MD is the principle investigator for Ono Pharmaceuticals. Dr. Batchelor will discuss the unapproved/investigational Clinical trials of investigational new agents in primary CNS lymphoma.

Andrew Evens, DO, MSc, FACP serves as a researcher and on the educational advisory board for Seattle Genetics, Abbvie, MorphoSys, Epizyme, Pharmacyclics, and Novartis, serves on the educational advisory board for Research to Practice, Cota, Curio, Hutchmed, OncLive, and Patient Power, and serves on the Research Advisory Board for Incyte, and Karyopharm. Dr. Evens will discuss the unapproved/investigational use regarding checkpoint inhibitors in lymphoma.

Timothy Fenske, MD, MS serves as a consultant and speaker for Adaptive Biotech, AstraZeneca, Bristol Meyers Squibb, MorphoSys, Seattle Genetics, and TG Therapeutics. He serves as a speaker for ADC Therapeutics and Kite Sanofi and as a consultant for Pharmacyclics/ AbbVie, Beigene and Biogen. He served as a consultant for CSL Therapeutics, Karyopharm, and Kyowa, as a speaker for Veristem, and as a consultant and speaker for Servier Pharmaceuticals.

Andres J.M. Ferreri, MD receives research grants from ADC Therapeutics, Bayer HealthCare Pharmaceuticals, Beigene, Bristol Myers Squibb, Genmab, Gilead, Hutchison Medipharma, Incyte, Janssen Research & Development, MEI Pharma, Novartis, PletixaPharm, Pharmacyclics, Protherics, Roche, and Takeda. She received speaker fees from Gilead and Roche and was a member of advisory boards of Gilead, Juno, Novartis, PletixaPharm, and Roche. Dr. Ferreri plans to discuss the unapproved/investigational use of Ibrutinib, lenalidomide, pomalidomide, tirabrutinib, CAR-T cells.

Jacklyn Gideon, MSN, AGPCNP-BC serves on the speaker’s bureau for Bristol Meyers Squibb and Pharmacyclics, and on the advisory board for Celgene.

Reem Karmali, MD serves on the speaker’s bureau for Kite, BeiGene, Morphosys, and Astra Zeneca, serves on the advisory board for Kite, Karyopharm, Janssen, Epizyme, BeiGene, Eusa, Morphosys, and Bristol Meyers Squibb, and has received research funding from Kite, Bristol Meyers Squibb, and Takeda.

Vaishalee P. Kenkre, MD serves as principle investigator for Novartis Pharmaceuticals Corporation, MEI Pharma, Inc., Celgene/BMS, Seattle Genetics, Inc., Gilead Sciences, and AbbVie. Dr. Kenkre will discuss unapproved/investigational use of utilizing checkpoint inhibitors in 2nd line therapy of classical Hodgkin lymphoma.

Justin P. Kline, MD serves as a consultant for Merck, Seagen, Kite/Gilead, TG Therapeutics, and Verastem, serves on the speaker’s bureau for Kite Gilead, and received research support from Merck, iTeos, and Verastem.

Robert Kridel, MD, PhD receives research funding from Roche, AbbVie, and Gilead Sciences.

Nicole Lamanna, MD receives research funding from AbbVie, AstraZeneca, Bei-Gene, Genentech, Oncternal, Octapharma, MindSight, EliLilly/Loxo, and TG Therapeutics. She serves on the advisory board for Janssen and Pharmacyclics. Dr. Lamanna will discuss the unapproved/investigational use of combinations of BTK+venetoclax +/- monoclonal antibody therapies for use in treatment of CLL and other novel agents in development for therapy of patients with CLL; noncovalent BTKi’s, etc.

Daniel J. Landsburg, MD receives research funding from Curis, and Triphase, and serves on the Karyopharm Data Safety Monitoring Board. He served on the Advisory board for Morphosys, Epizyme, and ADC Therapeutics. Dr. Landsburg will discuss the unapproved/investigational use of targeted therapies studied but not FDA-approved in R/R DLBCL.

Kami Maddocks, MD serves as a consultant for Incyte, BMS, ADC, Lilly, Genentech, Kite, Morphosys, Epizyme, Seattle Genetics, Beigene, Janssen, and AstraZeneca.

Neha Mehta-Shah serves as a consultant for Secura Bio, Daiichi Sankyo, and Ono and has received research funding from Bristol Meyers Squibb, Celgene, Verastem, Innate Pharmaceuticals, Corvus Pharmaceuticals, Genentech/Roche, Secura Bio and Daiichi Sankyo. Dr. Mehta- Shah served as a consultant for Karyopharm, Ono Pharma, C4 Therapeutics, and Kyowa Hakka Kirin. Dr. Mehta-Shah will discuss unapproved/investigational use of the novel therapeutics currently in trials.

Adam J. Olszewski, MD receives research funding from Genentech/Roche, Acrotech Pharma, Adaptive Biotechnologies, TG Therapeutics, Precision Bio, Genmab, and Celldex. Dr. Olszewski will discuss unapproved/investigational use of PI3K inhibitors, CDK4/6 inhibitors, venetoclax, devimistat, bispecific antibodies, antibody-drug conjugates, and CAR T-cells in Burkitt lymphoma.

Natasha N. Pettit, PharmD serves on the advisory committee for Eli Lilly. Dr. Pettit will discuss unapproved/investigational use of fluvoxamine for COVID-19 in patients with mild/moderate disease.

Tycel J. Phillips, MD serves on the advisory board for AstraZeneca, AbbVie, Beigene, Pharmacyclics, Genentech, BMS, Gilead, Eli Lily, ADCT Biopharma, Genmab, Morphosys/Incyte, Karyopharm, and Epyzime and receives research funding from AbbVie, BMS, and Genentech. Dr. Phillips will discuss the investigational/unapproved use of BTKi BCL2 inhibitors.

Craig A. Portell, MD served as a consultant for BeiGene, Kite/Gilead, Merck, and TG Therapeutics, has received grant funding for clinical study from AbbVie, and is the primary investigator for industry sponsored studies from Infinity, Acerta/Astra Zeneca, TG Therapeutics, BeiGene, Kite, Xencor, and SeaGen. Dr. Portell will discuss the investigational/unapproved use of novel agents in prevention of central nervous system progression of diffuse large B-cell lymphoma.

Peter A. Riedell, MD serves as a consultant and on the advisory board for BMS, Novartis, Kite/Gilead, Bayer, Beigene, Janssen, Karyopharm, and Takeda, and receives research funding from MorphoSys, CRISPR Therapeutics, Calibr, Xencor, Fate Therapeutics, and Tessa Therapeutics. Dr. Riedell will discuss the investigational/unapproved use of CD19-directed CAR-T cell therapy in 2nd line DLBCL.

Laurie Sehn MD, MPH serves as a consultant for AbbVie, Astra Zeneca, Celgene, Gilead, Incyte, Janssen, Kite, Roche/Genentech, Seattle Genetics, Teva, and TG Therapeutics, and research funding from Teva and Roche/Genentech. Dr. Sehn will discuss the investigational/unapproved use of novel agents in development for DLBCL.

David W. Scott, MBChB, PhD receives research funding from Janssen and Roche and is a consultant for Janssen, AbbVie, AstraZeneca, and Incyte. He has received research funding in the past from NanoString Technology.

Tanya Siddiqi, MD serves on the advisory board for Astra Zeneca, BeiGene, Kite Pharma, TG Therapeutics, and Celgene/BMS and on the speaker’s bureau for PCYC, Astra Zeneca, BeiGene, and Janssen. Dr. Siddiqi will discuss the investigational/unapproved use of JCAR014 CAR T cells liso-cel, JCAR017 CAR T cells, and ROR1-CAR T cells.

Sonali Smith, MD served as a consultant for Gamida Cell, Gilead, Bristol Meyers Squibb, Adaptive, ADC Therapeutics, Morphosys, Janssen, Karyopharm, and Bantam and as a speaker for ADC Therapeutics and Karyopharm. Dr. Smith served as a consultant for Genentech, TGTX, and Celgene. She has received research funding from Celgene, TGTX, Genetech, and Bristol Meyers Squibb. Dr. Smith will discuss the investigational/unapproved use of approved agents in unapproved settings or unapproved agents in development. She will disclose when this is the case.

Christian Steidl, MD serves as a consultant for Bayer, Seattle Genetics, and AbbVie, and receives research support from Epizyme, Trillium, and Bristol-Myers Squibb.

Patrick Stiff , MD receives research funding from Gamida-Cell, Karyopharm, Bristol Meyers Squibb, Cellectar, Macrogenics, Amgen, Kite Seattle Genetics, and Pfizer. Dr. Stiff serves as a consultant for CRISPR and MorphoSys.

Anna Sureda, MD, PhD  serves on the speaker’s bureau and advisory board for Takeda, BMS/Celegene, MSD, Novartis, Gilead Kite, GenMab, Janssen, and Sanofi, and receives research funding from Takeda. Dr. Sureda will discuss the investigational/unapproved use of Brentuximab vedotin and check point inhibitors used in non-approved indication in EU and eventually US too.

Girish Venkataraman ,MD served on the speaker’s bureau for EUSA Pharma.

Parameswaran Venugopal, MD serves as a consultant for BeiGene and Astra Zeneca.

Disclaimer

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright © 2022 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.